Uthando Nethemba

Stabilizers in ATTR-CM — tafamidis and acoramidis built the first hard-outcome standard of care, but the “next-generation” increment is not proven mortality superiority

—

by

itembalabantu
in

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All efficacy figures are attributed to the sponsoring trial or company (ATTR-ACT to Pfizer/NEJM 2018; ATTRibute-CM to BridgeBio/NEJM 2024). Cross-trial comparisons are not head-to-head. The “near-complete (≥90%) stabilization” claim is attributed to the BridgeBio label and mechanism argument and is kept separate from any hard-outcome superiority.

The 30-second version

  • What. In ATTR-CM (transthyretin amyloid cardiomyopathy), stabilizers are the oral, chronic drugs that hold the TTR tetramer together to stop dissociation and misfolding — rather than knocking TTR down. They are the only class with hard-outcome evidence: tafamidis established it first (ATTR-ACT, all-cause mortality HR 0.70, NEJM 2018), and acoramidis updated it (ATTRibute-CM, primary Win Ratio 1.8, NEJM 2024). Together they are the current standard of care (SoC).
  • So what. Acoramidis’s demonstrated increment is not hard-mortality superiority. In ATTRibute-CM, all-cause mortality alone was not statistically significant; the increment rides on a ~50% cut in cardiovascular hospitalization, biomarker improvement (NT-proBNP, 6-minute walk) and early (3-month) separation. There is no head-to-head trial of tafamidis versus acoramidis — the placebo-arm mortality gap (42.9% in ATTR-ACT vs 29.5% in ATTRibute-CM) reflects different eras and baseline severity, not a fair contest. The “near-complete (≥90%) stabilization” line is a mechanism/serum-TTR surrogate claim, not a clinical-superiority claim.
  • Now what. Precisely because stabilizers became the hard-outcome SoC, every later modality — the silencers (siRNA/ASO) and in-vivo editing (nex-z) — must now prove an add-on benefit on top of a stabilizer, not merely beat placebo. This SoC-establishment is half the origin of the Part-2 silencer puzzle: the background-therapy threshold. Read all figures as trial-attributed surrogates or endpoints from separate trials; cross-trial is not head-to-head.

The five-minute read

The one class with hard-outcome evidence — and why the “increment” splits in two

Among ATTR-CM therapies, stabilizers occupy a distinct position: they are oral and chronically dosed, and mechanistically they do not knock TTR down — they bind the tetramer to prevent dissociation and misfolding. This axis matters for two reasons. First, it is the only class to have established hard-outcome (mortality/cardiovascular) evidence first (tafamidis) and then updated it with a next-generation agent (acoramidis) — so it is the current standard of care. Second, once this SoC existed, the silencers (siRNA, ASO) and editing (nex-z) that followed were placed in a world where they must prove an add-on benefit on a stabilizer background. That is the root of the “add-on threshold” that the in-vivo editing series (Part 0) flagged.

The central question of this piece is: how much, and by what, did acoramidis update the standard tafamidis set? The short answer, stated up front: acoramidis’s increment is not a statistical win on hard mortality (all-cause mortality alone was non-significant in ATTRibute-CM). It rides on a large reduction in cardiovascular hospitalization, biomarker improvement, and a “near-complete stabilization (≥90%)” mechanism argument — and no head-to-head comparison of the two drugs exists (only cross-trial). The table below fixes what is demonstrated versus what is not.

Claim Status Basis (trial-attributed)
tafamidis hard outcome (mortality) Demonstrated ATTR-ACT all-cause mortality HR 0.70 (0.51–0.96) P=0.0259; ARR 13.3 pts (Pfizer/NEJM 2018)
tafamidis CV hospitalization Demonstrated RRR 0.68 (0.56–0.81) P<0.0001
acoramidis primary composite Demonstrated ATTRibute-CM Win Ratio 1.8 (1.42–2.22) p<0.0001 (BridgeBio/NEJM 2024)
acoramidis CV hospitalization Demonstrated 0.22 vs 0.45 per year, 50% reduction (0.36–0.70) P<0.0001
acoramidis all-cause mortality alone Not demonstrated (non-significant) All-cause mortality alone was not statistically significant in ATTRibute-CM
acoramidis > tafamidis (superiority) Not demonstrated / cannot be asserted No head-to-head; cross-trial only (different era, baseline severity)
“near-complete (≥90%)” superiority Mechanism/biomarker layer only Denaturation assay + serum-TTR surrogate; not a hard-outcome superiority basis
stabilizer SoC → add-on threshold Structurally demonstrated ATTRibute crossover to tafamidis; HELIOS-B / CARDIO-TTRansform background-therapy design (Part 2)
“A next-generation stabilizer” does not mean “proven to beat the prior standard on mortality.” Every figure is attributed to its sponsoring trial (ATTR-ACT to Pfizer/NEJM 2018; ATTRibute-CM to BridgeBio/NEJM 2024). The two trials are not a head-to-head comparison; placing their Win Ratio/HR side by side to rank the drugs is not valid without a matching-adjusted indirect comparison. The “near-complete (≥90%)” line is a BridgeBio label/mechanism claim describing degree of stabilization, not a clinical superiority declaration.

Deep dive

1. Background — the thesis: the first hard-outcome axis, but the “increment” divides

In ATTR-CM, stabilizers are the only class that is oral and chronically dosed while acting by holding the TTR tetramer together — preventing dissociation and misfolding rather than depleting TTR. Two facts make this axis pivotal. First, it is the only class that first established hard-outcome (mortality/cardiovascular) evidence in ATTR-CM (tafamidis) and then updated it with a next-generation agent (acoramidis); it is therefore today’s standard of care. Second, because this SoC exists, the silencers (siRNA, ASO) and editing (nex-z) that followed inherited the burden of proving an add-on benefit on a stabilizer background. The “add-on threshold” that the in-vivo editing landscape (Part 0) singled out is rooted here.

The chapter’s central question: how much, and by what, did acoramidis update the standard that tafamidis set? Pulling the conclusion forward — acoramidis’s increment is not a statistical win on hard mortality (all-cause mortality alone was non-significant in ATTRibute-CM); it rides on the reduction in CV hospitalization, biomarkers, and the “near-complete stabilization (≥90%)” mechanism claim — and the two drugs were never compared head-to-head (only cross-trial). The sections below narrow this with evidence.

2. tafamidis — ATTR-ACT: the first hard outcome (NEJM 2018)

Question (one line): in wild-type or hereditary ATTR-CM, does the TTR-tetramer stabilizer tafamidis reduce all-cause mortality and cardiovascular hospitalization versus placebo?

Method: ATTR-ACT, N=441, 30 months, double-blind randomized. The primary endpoint was a hierarchical composite of all-cause mortality (ACM) and frequency of CV hospitalization, analyzed by the Finkelstein-Schoenfeld (F-S) method (death ranked above hospitalization).

Primary result (as reported):

  • Primary hierarchical composite P=0.0006.
  • All-cause mortality 29.5% vs 42.9% (placebo), HR 0.70 (95% CI 0.51–0.96), P=0.0259 — absolute risk reduction (ARR) of 13.3 percentage points at 30 months.
  • CV hospitalization annualized rate 0.48 vs 0.70, relative risk ratio (RRR) 0.68 (95% CI 0.56–0.81), P<0.0001 — ARR 8.2 points.
  • A 30-month mortality number-needed-to-treat of ~7–8 derived from the reported ARR (a derived value, not stated explicitly in the paper — labeled derived).

Durability and approval: the survival benefit persisted on long-term follow-up (Circulation: Heart Failure 2021). Tafamidis received FDA approval in May 2019 (Vyndaqel/Vyndamax) and subsequently secured guideline standing (see §8). With this, tafamidis became the first disease-modifying standard of care in ATTR-CM.

3. acoramidis — ATTRibute-CM: updating the standard (NEJM 2024)

Question (one line): in wild-type or variant ATTR-CM, does acoramidis — designed as a near-complete stabilizer — improve a hierarchical composite of mortality, CV hospitalization, function and biomarkers versus placebo?

Method: ATTRibute-CM, N=632 (mean age 77, ~90% male), 30 months. The primary analysis used a four-step hierarchy assessed by Win Ratio, ordered: (1) all-cause mortality, (2) frequency of CV hospitalization, (3) change in NT-proBNP, (4) change in 6-minute walk distance (6MWD).

Primary result (as reported):

  • Primary Win Ratio 1.8 (precisely 1.77, 95% CI 1.42–2.22), p<0.0001.
  • About 58% of the winning comparisons were decided by the top two tiers (ACM + CV hospitalization) — those two alone were F-S significant.
  • All-cause mortality alone was not statistically significant (the key caveat) — commentators and authors point to a less sick baseline population than ATTR-ACT (placebo-arm mortality 29.5% vs 42.9% in ATTR-ACT).
  • Composite of “all-cause mortality or first CV hospitalization”: 35.9% vs 50.5%, HR 0.64 (95% CI 0.50–0.83), P=0.0008 (JACC 2024).
  • CV hospitalization annualized rate 0.22 vs 0.45, a 50% relative reduction (95% CI 0.36–0.70), P<0.0001.
  • NT-proBNP improved (declined) in 45% vs 9%; 6MWD improved (increased) in 40% vs 22%.
  • 30-month survival in the treatment arm 80.7%. Separation of effect began by 3 months (described by BridgeBio as the earliest separation).
  • Open-label extension (OLE) at 42 months: “all-cause mortality or first CV hospitalization” HR 0.57 (95% CI 0.46–0.72), P<0.0001 (favoring continued treatment).

Approval: FDA approval on 22 November 2024 (Attruby) — the label states “near-complete (≥90%) TTR stabilizer,” with an indication to reduce CV death and CV hospitalization, dosed orally twice daily.

4. Head-to-head absent — “near-complete stabilization” as demonstration vs marketing

Mechanistic difference (confirmed): acoramidis was designed to mimic the stabilizing T119M variant, so unlike tafamidis’s predominantly entropic (hydrophobic) binding it holds the tetramer via enthalpic (hydrogen-bond) binding. In in-vitro/ex-vivo acid-denaturation assays, acoramidis reaches ≥90% stabilization (“near-complete”) while tafamidis and diflunisal are reported as partial stabilizers (PMC12333512). A rise in serum TTR (sTTR) independently predicted improved survival (JACC 2025), and adding tafamidis to acoramidis did not raise sTTR further (no additional stabilization benefit).

But the nature of the “increment” must be separated:

  • Hard-mortality superiority was not demonstrated. In ATTRibute-CM, all-cause mortality alone was non-significant, whereas in ATTR-ACT tafamidis was significant on all-cause mortality alone (HR 0.70). So the proposition “near-complete stabilization extends life longer” has never been established head-to-head.
  • “Near-complete (≥90%)” is a mechanism/biomarker (sTTR, denaturation) claim, not a claim of clinical hard-endpoint superiority over tafamidis. The label language describes the degree of stabilization (≥90%); it does not declare comparative superiority.
  • Cross-trial contamination: ATTR-ACT (2018) and ATTRibute-CM (2024) differ in era, background heart-failure care and baseline severity (placebo mortality 42.9% vs 29.5%; “older but less sick”). Ranking the two by placing their Win Ratio/HR side by side is not valid without a matching-adjusted indirect comparison (MAIC).

Summary: acoramidis’s demonstrated increment is a large reduction in CV hospitalization (50% per year), early separation (3 months) and biomarker improvement. All-cause mortality superiority, and superiority over tafamidis, are not demonstrated (no head-to-head). “Near-complete stabilization” is a basis for mechanistic differentiation, not for hard-outcome superiority.

5. The background-therapy threshold — the bridge to Part 2

The moment a stabilizer became the SoC on hard outcomes, every later modality entered a world where it must prove an increment on top of a stabilizer, not just beat placebo. ATTRibute-CM itself foreshadows this: during the trial (after 12 months), 14.5% of the acoramidis arm and 21.8% of the placebo arm added tafamidis (ethically permitted once tafamidis became SoC). Concomitant tafamidis was reported not to materially affect the acoramidis effect, but that crossover is itself a signal of an era in which a pure placebo control is becoming difficult.

This threshold carries directly into the silencers and editing. The central contrast of Part 0 — siRNA (HELIOS-B, succeeding even at ~60% monotherapy, HR 0.72) versus ASO (CARDIO-TTRansform, mostly on stabilizer background, missing its primary) — may be less a difference of modality than a manifestation of the “add-on-on-a-stabilizer threshold.” In other words, this chapter (the establishment of stabilizer SoC) already creates half the cause of the Part-2 puzzle. Detail follows in Part 2.

6. The skeptic’s bottom line

  • Individual trial endpoints are verified-clean: the primary-endpoint figures (HR, Win Ratio, RRR, CI, p) for each trial are confirmed against the NEJM/JACC primary sources.
  • Win Ratio interpretation: the primary was positive, but the four-step hierarchy includes biomarkers (NT-proBNP, 6MWD). That said, the top two tiers (ACM + CV hospitalization) alone were F-S significant (~58% contribution), so “the biomarkers did all the work” is a weak objection. Even so, the non-significance of all-cause mortality alone must be stated explicitly.
  • Near-complete stabilization — demonstration vs marketing: the ≥90% figure rests on assay and serum-TTR (surrogate) evidence. It must not be extended into a claim of hard-endpoint superiority.
  • Cross-trial contamination: ATTR-ACT and ATTRibute-CM cannot be ranked side by side (no MAIC; different era and severity). Any “acoramidis is better / worse” statement is an escalation item and is avoided here.
  • Overall verdict: proceed-with-caveats. The individual trial numbers are fixed against primary sources; but four caveats must be exposed at Tier-1 level: (1) acoramidis all-cause mortality alone is non-significant; (2) no head-to-head exists (cross-trial only); (3) “near-complete” is a mechanism/surrogate claim; (4) the stabilizer SoC creates the downstream add-on threshold.

7. What to watch (falsifiable)

  • P1: if a matching-adjusted indirect comparison (MAIC) is performed, acoramidis’s all-cause (hard-mortality) advantage will not reach significance versus tafamidis — the difference sits in CV hospitalization, biomarkers and era effects. (Verified by future adjusted indirect comparisons / real-world data.)
  • P2: the causal chain that treats rising sTTR as a surrogate (“near-complete → better”) weakens if long-term registry/RWD shows the sTTR increase does not predict mortality reduction beyond a biomarker. (Verified by OLE / registry long-term follow-up.)
  • P3: in add-on trials of silencers/editing on a stabilizer background, the higher the concomitant-stabilizer share, the smaller the hard-outcome increment (the SoC raises the threshold) — confirmed or refuted in Part 2. (Verified by eplontersen full data at ESC 2026-08 and HELIOS-B subgroups.)

8. CKM framing and guideline alignment (link to Part 2)

ATTR-CM is the heart-failure (HFpEF/HFmrEF) extreme of the CKM spectrum, and stabilizers differ in character from the metabolic heart-failure classes (SGLT2i, GLP-1, finerenone) in that they are disease-modifying against the protein-misfolding cause itself. Guideline alignment:

  • ESC 2021 cardiac amyloidosis position statement and ACC 2023 Expert Consensus Decision Pathway (JACC): tafamidis recommended for NYHA I–II ATTR-CM.
  • AHA/ACC/HFSA 2022 heart-failure guideline: tafamidis recommended (through NYHA III) to reduce CV morbidity and mortality.
  • Acoramidis, approved November 2024, is entering the guideline-revision cycle (most current documents remain tafamidis-centric).

Part 2 (silencers) enters a world where a therapy must prove an add-on benefit on top of this SoC — testing head-on the hypothesis that the threshold stabilizers built is the background variable behind the siRNA-success / ASO-miss contrast.

References

Disclosure

This post is for information only and is not investment advice, and not medical advice. Treatment decisions should always be made with your own clinician.

COI note: this post describes listed pharmaceutical companies (Pfizer, PFE — tafamidis; BridgeBio, BBIO — acoramidis) and their sponsored trials in a descriptive, neutral context. Every efficacy figure is attributed to its sponsoring trial: ATTR-ACT numbers to Pfizer / NEJM 2018; ATTRibute-CM numbers to BridgeBio / NEJM 2024. The “near-complete (≥90%) stabilization” language is attributed to the BridgeBio label and mechanism argument and is kept separate from any hard-outcome superiority claim. There is no head-to-head trial of tafamidis versus acoramidis; the two trials differ in era and baseline severity, so cross-trial figures are not a fair comparison and no superiority is asserted. Quantitative claims are attributed to the vendor, author or trial. Competitive statements are factual, neutral descriptions and are not buy/sell implications for any security. The author holds no position in, and has no financial interest in, the companies named.

Comments

Leave a comment